Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 8, 2022
Trends of recanalization therapies and state of art for ischemic stroke treatment in Campania region, ItalyEmanuele Spina, Paolo Candelaresi, Giampiero Volpe, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|November 9, 2020
The Impact of Covid-19 Lockdown on Stroke Admissions and Treatments in CampaniaPaolo Candelaresi, Valentino Manzo, Giovanna Servillo, et al.The Journal of Headache and Pain|November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patientsPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.The Journal of Headache and Pain|March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 studyPiero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.Neurology and Therapy|March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 StudyPiero Barbanti, Gabriella Egeo, Stefania Proietti, et al.Neurology and Therapy|June 9, 2026
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III StudyPiero Barbanti, Cinzia Aurilia, Massimo Filippi, et al.Pageof 5